

Hepatitis E

HEV-IgM

IgM ANTIBODY TO HEPATITIS E VIRUS ELISA KIT

Two-step Incubation, Antibody Capture Principle

INSTRUCTIONS FOR USE

INTENDED USE

This HEV IgM kit is an enzyme-linked immunosorbent assay (ELISA) for qualitative determination of IgM-class antibodies to hepatitis E virus in human serum or plasma. It is intended for use in clinical laboratories for diagnosis and management of patients related to infection with hepatitis E virus.

SUMMARY

Hepatitis E virus (HEV) is a non-enveloped, single-stranded RNA virus identified in 1990. Infection with HEV induces acute or sub-clinical liver diseases similar to hepatitis A. HEV infections, endemic and frequently epidemic in developing countries, is seen also in developed countries in a sporadic form with or without a history of traveling to endemic area. The overall case-fatality is 0.5~3%, and much higher (15~25%) among pregnant women. A hypothesis that HEV infection is a zoonosis was presented in 1995. Then a swine HEV and later an avian HEV were identified and sequenced separately in 1997 and 2001. Since then, HEV infection include anti-HEV, viremia and feces excretion of HEV was seen in a wide variety of animals, i.e., swine, rodents, wild monkeys, deer, cow, goats, dogs and chicken in both the developing and developed countries. A direct testimony was reported that the consumption of uncooked deer meat infected with HEV led to acute hepatitis E in human. And HEV genome sequences can be detected in pork livers available in the supermarkets in Japan.

With the discovery of conformational epitopes in HEV, HEV serology was further explored and understood. The phenomenon of long-lasting and protective antibodies to HEV was observed which greatly enhance the understanding to the diagnosis, epidemiology, zoonosis-related studies and vaccine development.

PRINCIPLE OF THE ASSAY

This kit is a two-steps incubation, solid phase antibody capture ELISA assay in which polystyrene microwell strips are pre-coated with antibodies directed to human immunoglobulin M proteins (anti- μ chain). The patient's serum/plasma sample is added and during the first incubation step, any IgM-class antibodies will be captured in the wells. After washing out all the other components of the sample and in particular IgG-class antibodies, the specific HEV IgM captured on the solid phase is detected by the addition of recombinant HEV ORF2 antigens conjugated to horseradish peroxidase (HRP-Conjugate). During the second incubation, the HRP-conjugated antigens will specifically react only with HEV IgM antibodies and after washing to remove the unbound HRP-Conjugate, Chromogen solutions are added into the wells.

In presence of (anti- μ) - (anti-HEV-IgM) - (HEV Ag-HRP) immunocomplex, the colorless Chromogens are hydrolyzed by the bound HRP-Conjugate to a blue-colored product. The blue

color turns yellow after stopping the reaction with sulfuric acid. The amount of color intensity can be measured and is proportional to the amount of antibody captured in the wells, and to the sample respectively. Wells containing samples negative for HEV IgM remain colorless.

Assay principle scheme: Antibody Capture ELISA

$Ab(p)+IgM(s) \rightarrow [Ab(p)-IgM(s)]+ENZ \rightarrow [Ab(p)-IgM(s)-ENZ] \rightarrow blue \rightarrow yellow (+)$

$Ab(p) \rightarrow [Ab(p)] +ENZ \rightarrow [Ab(p)] \rightarrow no\ color (-)$

Incubation1	Incubation2	Immobilized Complex	Coloring	Results
30min.	30 min.			15 min.

Ab(p) – pre-coated anti-IgM antibodies (anti- μ chain);

IgM(s) – HEV IgM antibodies in sample;

ENZ – HRP conjugated HEV antigens;

COMPONENTS



96 Tests

- **MICROWELL PLATE** 1plate
Blank microwell strips fixed on white strip holder. The plate is sealed in aluminium pouch with desiccant.
8 × 12/12 × 8-well strips wells per plate. Each well contains anti-IgM antibodies (anti- μ chain). The microwell strips can be broken to be used separately. Place unused wells or strips in the plastic sealable storage bag together with the desiccant and return to 2~8°C.
 - **NEGATIVE CONTROL** 1vial
Yellowish liquid filled in a vial with green screw cap.
0.5ml per vial.
Protein-stabilized buffer tested non reactive for HEV IgM.
Preservatives: 0.1% ProClin 300.
Ready to use as supplied.
Once open, stable for one month at 2-8°C
 - **POSITIVE CONTROL** 1vial
Red-colored liquid filled in a vial with red screw cap.
0.5ml per vial.
Purified HEV IgM class antibodies diluted in protein-stabilized buffer.
Preservatives: 0.1% ProClin 300.
Ready to use as supplied.
Once open, stable for one month at 2-8°C.
 - **SPECIMEN DILUENT** 1vial
Blue liquid in a white vial with blue screw cap.
12ml per vial.
Serum base, casein, and sucrose solution
Ready to use as supplied.
Once open, stable for one month at 2-8°C.
 - **HRP-CONJUGATE REAGENT** 1vial
Red-colored liquid in a white vial with red screw cap.
12ml per vial.
Horseradish peroxidase-conjugated recombinant HEV antigens.
Ready to use as supplied.
Once open, stable for one month at 2-8°C
 - **STOCK WASH BUFFER** 1bottle
Colorless liquid filled in a clear bottle with white screw cap.
50ml per bottle.
PH 7.4, 20 × PBS (contains detergent Tween-20)
- DILUTE BEFORE USE** -The concentrate must be diluted **1 to 20** with distilled/ deionized water before use. Once diluted, stable for one week at room temperature, or for two weeks when stored at 2-8°C.
- **CHROMOGEN SOLUTION A** 1vial
Colorless liquid filled in a white vial with green screw cap.

7ml per vial.

Urea peroxide solution.

Ready to use as supplied.

Once open, stable for one month at 2-8°C

● **CHROMOGEN SOLUTION B** 1vial

Colorless liquid filled in a black vial with black screw cap.
TMB solution (Tetramethyl benzidine dissolved in citric acid).
7ml per vial.

Ready to use as supplied.

Once open, stable for one month at 2-8°C

● **STOP SOLUTION** 1vial

Colorless liquid in a white vial with white cap.
7ml per vial.

Diluted sulfuric acid solution (2.0M H₂SO₄).

Ready to use as supplied.

● **PLASTIC SEALABLE BAG** 1unit

For enclosing the strips not in use.

● **CARDBOARD PLATE COVER** 2sheets

To cover the plates during incubation and prevent evaporation or contamination of the wells.

● **PACKAGE INSERTS** 1copy

**ADDITIONAL MATERIALS AND INSTRUMENTS
REQUIRED BUT NOT PROVIDED**

- Freshly distilled or deionized water.
- Disposable gloves and timer.
- Appropriate waste containers for potentially contaminated materials.
- Disposable V-shaped troughs.
- Dispensing system and/or pipette (single or multichannel), disposable pipette tips.
- Absorbent tissue or clean towel.
- Dry incubator or water bath, 37±0.5°C.
- Microshaker for dissolving and mixing conjugate with samples.
- Microwell reader, single wavelength 450nm or dual wavelength 450nm and 630nm.
- Microwell aspiration/wash system.

**SPECIMEN COLLECTION, TRANSPORTATION AND
STORAGE**

1. **Sample Collection:** Either fresh serum or plasma samples can be used for this assay. Blood collected by venipuncture should be allowed to clot naturally and completely – the serum/plasma must be separated from the clot as early as possible as to avoid hemolysis of the RBC. Care should be taken to ensure that the serum samples are clear and not contaminated by microorganisms. Any visible particulate matters in the sample should be removed by centrifugation at 3000 RPM for at least 20 minutes at room temperature, or by filtration on 0.22µ filters. Plasma samples collected into EDTA, sodium citrate or heparin may be tested, but highly lipaemic, icteric, or hemolized samples should not be used as they could give erroneous results in the assay. Do not heat inactivate samples. This can cause sample deterioration.
2. **Transportation and Storage:** Store samples at 2-8°C. Samples not required for assaying within 3 days should be stored frozen (-20°C or lower). Multiple freeze-thaw cycles should be avoided. For shipment, samples should

be packaged and labeled in accordance with the existing local and international regulations for transport of clinical samples and ethological agents.

SPECIAL INSTRUCTIONS FOR WASHING

1. A good washing procedure is essential to obtain correct and precise analytical data.
2. It is therefore recommended to use a good quality ELISA microplate washer, maintained at the best level of washing performances. In general, no less than 5 automatic washing cycles of 350-400µl/well are sufficient to avoid false positive reactions and high background.
3. To avoid cross-contaminations of the plate with sample or HRP-conjugate, after incubation do not discard the content of the wells but allow the plate washer to aspirate it automatically.
4. Anyway, we recommend calibrating the washing system on the kit itself in order to match the declared analytical performances. Assure that the microplate washer liquid dispensing channels are not blocked or contaminated and sufficient volume of Wash buffer is dispensed each time into the wells.
5. In case of manual washing, we suggest to carry out 5 cycles, dispensing 350-400µl/well and aspirating the liquid for 5 times. If poor results (high background) are observed, increase the washing cycles or soaking time per well.
6. In any case, the liquid aspirated out the strips should be treated with a sodium hypochlorite solution at a final concentration of 2.5% for 24 hours, before liquids are wasted in an appropriate way.
7. The concentrated Washing solution should be diluted **1 to 20** before use. For one plate, mix 50 ml of the concentrate with 950ml of water for a final volume of 1000ml diluted Wash Buffer. If less than a whole plate is used, prepare the proportional volume of solution.

STORAGE AND STABILITY

The components of the kit will remain stable through the expiration date indicated on the label and package when stored between 2-8 °C, **do not freeze**. To assure maximum performance of this HEV IgM ELISA kit, during storage protect the reagents from contamination with microorganism or chemicals.

PRECAUTIONS AND SAFETY

This kit is intended **FOR IN VITRO USE ONLY** IVD

FOR PROFESSIONAL USE ONLY

The ELISA assay is a time and temperature sensitive method. To avoid incorrect result, strictly follow the test procedure steps and do not modify them.

1. Do not exchange reagents from different lots, or use reagents from other commercially available kits. The components of the kit are precisely matched as to achieve optimal performance during testing.
2. Make sure that all reagents are within the validity indicated on the kit box and are of the same lot. Never use reagents beyond the expiry date stated on reagents labels or on the kit box.
3. **CAUTION - CRITICAL STEP:** Allow the reagents and samples to stabilize at room temperature(18-30°C) before use.

4. Shake reagent gently before, and return to 2-8 °C immediately after use.
5. Use only sufficient volume of sample as indicated in the procedure steps. Failure to do so, may cause in low sensitivity of the assay.
6. Do not touch the bottom exterior of the wells; fingerprints or scratches may interfere with microwell reading.
7. When reading the results, ensure that the plate bottom is dry and there are no air-bubbles inside the wells.
8. Never allow the microplate wells to dry after the washing step. Immediately proceed to the next step. Avoid the formation of air-bubbles when adding the reagents.
9. Avoid assay steps long time interruptions. Assure same working conditions for all wells.
10. Calibrate the pipette frequently to assure the accuracy of samples/reagents dispensing. Always use different disposal pipette tips for each specimen and reagents as to avoid cross-contaminations. Never pipette solutions by mouth. The use of automatic pipettes is recommended.
11. Assure that the incubation temperature is 37°C inside the incubator.
12. When adding samples, avoid touching the well's bottom with the pipette tip.
13. When reading the results with a plate reader, it is recommended to determine the absorbance at 450nm or at 450nm with reference at 630nm.
14. All specimens from human origin should be considered as potentially infectious.
15. Materials from human origin may have been used in the kit. These materials have been tested with tests kits with accepted performance and found negative for antibodies to HIV ½, HCV, TP and HBsAg. However, there is no analytical method that can assure that infectious agents in the specimens or reagents are completely absent. Therefore, handle reagents and specimens with extreme caution as if capable of transmitting infectious diseases. Strict adherence to GLP (Good Laboratory Practice) regulations can ensure the personal safety. Never eat, drink, smoke, or apply cosmetics in the assay laboratory.
16. Bovine derived sera may have been used in this kit. Bovine serum albumin (BSA) and fetal calf sera (FCS) are derived from animals from BSE/TSE free-geographical areas.
17. The pipette tips, vials, strips and sample containers should be collected and autoclaved for 1hour at 121°C or treated with 10% sodium hypochlorite for 30minutes to decontaminate before any further steps for disposal.
18. The Stop solution (2M H₂SO₄) is a strong acid. Corrosive. Use it with appropriate care. Wipe up spills immediately or wash with water if come into contact with the skin or eyes. ProClin 300 used as a preservative can cause sensation of the skin.
19. The enzymatic activity of the HRP-conjugate might be affected from dust, reactive chemical, and substances like sodium hypochlorite, acids, alkalins etc. Do not perform the assay in the presence of such substances.
20. Materials Safety Data Sheet (MSDS) available upon request.
21. If using fully automated microplate processing system, during incubation, do not cover the plates with the plate cover. The tapping out of the remainders inside the plate after washing, can also be omitted.

ASSAY PROCEDURE

- Step1 Reagents Preparation:** Allow the reagents and samples to reach room temperature. (18-30°C) for at least 15-30minutes. Check the Wash buffer concentrate for the presence of salt crystals. If crystals have formed in the solution, resolubilize by warming at 37°C until crystals dissolve. Dilute the Wash buffer **1:19** with distilled or deionized water. Use only clean vessels to dilute the Wash buffer. Mark three wells as Negative control (e.g. **B1, C1, D1**), two wells as Positive control (e.g. **E1, F1**) and one Blank. (e.g. **A1**, neither samples or HRP-Conjugate should be added into the Blank well). If the results will be determined by using dual wavelength plate reader, the requirement for use of Blank well could be omitted. Use only number of strips required for the test.
- Step2 Adding Diluent:** Add **100µl** Specimen Diluent into each well.
- Step3 Adding Sample:** Add **10µl** of samples and **10µl** Positive and Negative controls and into their respective wells. **Note: Use a separate disposal pipette tip for each specimen, Negative and Positive Control as to avoid cross-contamination.**
- Step4 Incubating Sample (1):** Cover the plate with the plate cover and incubate for **30minutes at 37°C**. It is recommended to use thermostat-controlled water tank to assure the temperature stability and humidity during incubation. If dry incubator is used, do not open the door frequently.
- Step5 Washing(2):** After the end of the incubation remove and discard the plate cover. Wash each well **5times** with diluted Washing buffer. Each time allow the microwells to soak for **30-60 seconds**. After the final washing cycle, turn down the plate onto blotting paper or clean towel and tap it to remove any remainders.
- Step6 Adding HRP-Conjugate:** Add **100µl** of HRP-Conjugate Reagent into each well except for the Blank.
- Step7 Incubating HRP-Conjugate(2):** Cover the plate with the plate cover and incubate for **30minutes at 37°C**.
- Step8 Washing(2):** Remove and discard the plate sealer. Aspirate the liquid and rinse each well **5times** with Wash buffer (as step 5). After the final washing cycle, turn the strips plate and tap out any remainders.
- Step9 Coloring:** Add **50µl** of Chromogen A and **50µl** Chromogen B solution into each well including the **Blank**. Incubate the plate at **37°C for 15minutes avoiding light**. The enzymatic reaction between the Chromogen solutions and the HRP-Conjugate produces blue color in Positive control and HEV IgM positive sample wells.
- Step10 Stopping Reaction:** Using a multichannel pipette or manually, add **50µl** Stop solution into each well and mix gently. Intensive yellow color develops in Positive control and HEV IgM positive sample wells.
- Step11 Measuring the Absorbance:** Calibrate the plate reader with the Blank well and read the absorbance at **450nm**. If a dual filter instrument is used, set the reference wavelength at **630nm**. Calculate the Cut-off value and evaluate the results. (**Note:** read the absorbance within **5minutes** after stopping the reaction)

INTERPRETATION OF RESULTS AND QUALITY CONTROL

Each microplate should be considered separately when calculating and interpreting results of the assay, regardless of

the number of plates concurrently processed. The results are calculated by relating each sample's optical density (OD) value to the Cut-off value (C.O.) of the plate. If the Cut-off reading is based on single filter plate reader, the results should be calculated by subtracting the Blank well OD value from the print report values of samples and controls. In case the reading is based on Dual filter plate reader, do not subtract the Blank well OD from the print report values of samples and controls.

1. Calculation of Cut-off value (C.O.) = *Nc + 0.26

*Nc = the mean absorbance value for three negative controls.

Example:

1. Calculation of Nc:

Well No	B1	C1	D1
Negative controls OD value	0.02	0.012	0.016
Nc=0.016			

2. Calculation of Cut-off : C.O. = 0.016 + 0.26 = 0.276

If one of the Negative control values does not meet the Quality control range specifications, it should be discarded and the mean value is calculated again using the remaining two values. If more than one negative control OD value does not meet the Quality control range specifications, the test is invalid and must be repeated.

2. Quality control range:

The test results are valid if the Quality control criteria are verified. It is recommended that each laboratory must establish appropriate quality control system with quality control material similar to or identical with the patient sample being analyzed.

- The OD value of the Blank well, which contains only Chromogens and Stop solution, is less than 0.080 at 450 nm.
- The OD value of the Positive control must be equal to or greater than 0.800 at 450/630nm or at 450nm after blanking.
- The OD value of the Negative control must be less than 0.100 at 450/630nm or at 450nm after blanking.

3. Interpretations of the results:

(S = the individual absorbance (OD) of each specimen)

Negative Results (S/C.O. < 1) : Samples giving absorbance less than the Cut-off value are negative for this assay, which indicates that no IgM-class antibodies to hepatitis E virus have been detected with this kit, therefore there are no serological indications for current infection with HEV.

Positive Results (S/C.O. ≥ 1) : Samples giving an absorbance equal to, or greater than the Cut-off value are considered initially reactive, which indicates that IgM-class antibodies to hepatitis E virus have probably been detected using this HEV IgM ELISA kit. Retesting in duplicates of any initially reactive sample is recommended. Repeatedly reactive samples could be considered positive for IgM-class antibodies to HEV and therefore the patient is probably infected with hepatitis E virus.

Borderline (S/C.O. = 0.9-1.1) : Samples with absorbance to Cut-off ratio between 0.9 and 1.1 are considered borderline and retesting of these samples in duplicates is recommended to confirm the results. Repeatedly positive samples could be considered positive for IgM-class antibodies to HEV.

TEST PERFORMANCE AND EXPECTED RESULTS

Experiments data from laboratory testing: C.O. = 0.286. The Absorbance (OD) Values are given below:

Negative sample			Positive sample		
1	2	3	Control	Weak	Strong
0.028	0.008	0.042	1.978	2.610	2.562

Performance characteristics of **Sensitivity** and **specificity**.

Reagents	HEV IgM		Reference HEV IgM EIA	
	- / total	Specificity	+ / total	Sensitivity
HEV IgM EIA	273/273	100.0	47/48	97.9
EIA IgM	264/273	96.7	35/48	72.9
EIA IgG	233/273	85.4	45/48	93.8

Site	HEV IgM		Ref. HEV IgM EIA		Ref. HEV IgG EIA	
	+ / total	Sens.	+ / total	Sens.	+ / total	Sens.
1	135/140	96.4%	112/140	80.0%	---	---
2	47/48	97.9%	35/48	72.9%	45/48	93.8%
3	123/126	97.6%	109/126	86.5%	---	---
Total	305/314	97.1%	256/314	81.5%	45/48	93.8%

Reproducibility	Specimen Type	N	Within run		Between run	
			Mean S/CO	CV%	Mean S/CO	CV%
	Weak positive	10	3.93	8.1%	3.85	8.5%
	Moderate positive	10	9.52	7.3%	9.37	7.6%
	Strong positive	10	17.80	4.6%	17.67	5.1%

LIMITATIONS

- Non-repeatable positive result may occur due to the general biological and biochemical characteristics of ELISA assays. The test is designed to achieve very high performance characteristics of sensitivity and specificity. However, antibodies may be undetectable during the early stages of the disease and in some immunosuppressed individuals.
- If, after retesting of the initially reactive samples, the assay results are negative, these samples should be considered as non-repeatable (false positive) and interpreted as negative. As with many very sensitive ELISA assays, false positive results can occur due to the several reasons, most of which are related but not limited to inadequate washing step.
- Any positive result must be interpreted in conjunction with patient clinical information and other laboratory testing results.
- Common sources for mistakes: kits beyond the expiry date, bad washing procedures, contaminated reagents, incorrect assay procedure steps, insufficient aspiration during washing, failure to add samples or reagents, equipment, timing, volumes, sample nature and quality.
- The prevalence of the marker will affect the assay's predictive values.
- False negative results can occur from inhibition of specific

IgM in the presence of high titers of specific IgG. The removal of IgG can be helpful to prevent false negative results and methods for this are given elsewhere.

- This kit is intended ONLY for testing of individual serum or plasma samples. Do not use it for testing of cadaver samples, saliva, urine or other body fluids, or pooled (mixed) blood.
- This is a qualitative assay and the results cannot be used to measure antibodies concentrations.

INDICATIONS OF INSTABILITY OR DETERIORATION OF THE REAGENTS

- Values of the Positive or Negative controls, which are out of the indicated Quality control range, are indicator of possible deterioration of the reagents and/or operator or equipment errors. In such case, the results should be considered as invalid and the samples must be retested. In case of constant erroneous results classified as due to deterioration or instability of the reagents, immediately substitute the reagents with new ones.
- If after mixing of the Chromogen A and B solutions into the wells, the color of the mixture turns blue within few minutes, do not continue carrying out the testing and replace the reagents with fresh ones.

VALIDITY

Please do not use this kit beyond the expiry date indicated on the kit box and reagent labels.

REFERENCES:

- Reyes GR, Purdy MA, Kim JP, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. *Science* 1990; 247: 1335-1339.
- Clayson E, Innis B, Myint K, et al. Detection of hepatitis E virus infections among domestic swine in the Kathmandu Valley of Nepal. *Am J Trop Med Hyg.* 1995;53:228-232.
- Meng XJ, Purcell RH, Halbur PG, et al. A novel virus in swine is closely related to the human hepatitis E virus. *Proc Natl Acad Sci USA*, 1997, 94: 9860-9865.
- Tei S, Kitajima N, Takahashi K, et al. Zoonotic transmission of hepatitis E virus from deer to human beings. *Lancet* 2003; 362(9381):371
- Zheng YJ, Zhang J, Xia NS. A debate about that hepatitis E is a zoonosis. *Chinese J Zoonosis* (in press)
- Wang YC, Zhang HY, Xia NS, et al. Prevalence, Isolation, and Partial Sequence Analysis of Hepatitis E Virus From Domestic Animals in China. *J Med Virol* 2002;67:516-521
- Zhang J, Ge SX, Huang GY, et al. Two Hepatitis E Virus Neutralization Sites analyzed by monoclonal antibodies raised against a recombinant peptide of virus capsid protein. *J Virol* 2003(in press)
- Zhang J, Ge SX, Huang GY, et al. Evaluation of antibody based and nucleic acid based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model. *J Med Virol* 2003 (in press)
- Li SW, Zhang J, He ZQ, et al. The study of aggregate of the ORF2 peptide of hepatitis E virus expressed in *Escherichia Coli*. *Chinese J Biotechnology* 2002. 18 (4): 463-467
- Gu Y, Zhang J, Li SW, et al. Characterization of the anti-HEV ORF2 monoclonal antibodies by biosensor. *Chin J Cell Mol Immunol*, 2002, 18(6): 617-620
- Li XL, Ren H, Liang XH, et al. Detection of anti-virus antibody in sera from patients with hepatitis E after ten-year-infection. *Endemic Diseases Bulletin* 2002. 17 (3): 14-17

SUMMARY OF THE ASSAY PROCEDURE:

Add sample diluent	100µl
Add sample	10µl
Incubate	30minutes
Wash	5times
Add HRP-Conjugate	100µl
Incubate	30minutes
Wash	5times
Coloring	50µl A + 50µl B
Incubate	15 minutes
Stop the reaction	50µl stop solution
Read the absorbance	450nm or 450/630 nm

Example of controls/samples dispensing scheme

SUMMARY OF THE COMPONENTS OF THE KIT:			7	12
A	Blank	S3				
Microwell plate			96, 8 wells			
B	Neg.	...				
Positive/Negative control			One each/ 0.5ml			
C	Neg.	...				
Sample Diluent			One/ 12ml			
E	Pos.	...				
HRP-Conjugate			One/ 12ml			
F	Pos.	...				
Wash Buffer			One/ 50ml			
H	S2	...				
Chromogen A/B/Stop solution			One each/ 7ml			

Note: the components of individual kits are not interchangeable